Seeking Alpha

Oncolytics Biotech (ONCY) -13.4% premarket after saying it will expand enrollment in its Phase...

Oncolytics Biotech (ONCY) -13.4% premarket after saying it will expand enrollment in its Phase III study of Reolysin, a possible treatment for head and neck cancers, after observing different responses in two different groups of patients.
Comments (1)
  • billyboys2
    , contributor
    Comments (3) | Send Message
     
    this could be positive
    14 Sep 2012, 10:04 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs